FierceBiotech ٣١ مايو ٢٠٢٦ ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
FierceBiotech ٣٠ مايو ٢٠٢٦ In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
FierceBiotech ٣٠ مايو ٢٠٢٦ ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
FierceBiotech ٢٩ مايو ٢٠٢٦ Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
FierceBiotech ٢٩ مايو ٢٠٢٦ AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
FierceBiotech ٢٩ مايو ٢٠٢٦ Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
FierceBiotech ٢٩ مايو ٢٠٢٦ ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
FierceBiotech ٢٩ مايو ٢٠٢٦ ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger
FierceBiotech ٢٩ مايو ٢٠٢٦ Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field
FierceBiotech ٢٩ مايو ٢٠٢٦ Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
FierceBiotech ٢٨ مايو ٢٠٢٦ Icon ends internal accounting investigation, finds it overstated revenue in prior years
FierceBiotech ٢٨ مايو ٢٠٢٦ FDA extends Beren’s rare disease review after info request, further stretching saga
FierceBiotech ٢٨ مايو ٢٠٢٦ Human Longevity launches newco, teams with Insilico for AI-powered longevity research
FierceBiotech ٢٨ مايو ٢٠٢٦ Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals
FierceBiotech ٢٨ مايو ٢٠٢٦ GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease